Стратегия контроля ритма при фибрилляции предсердий: современное состояние проблемы
https://doi.org/10.35336/VA-1335
EDN: BYUMYF
Аннотация
Применение раннего контроля ритма и катетерной аблации является активно развивающимся направлением в терапии фибрилляции предсердий. В обзоре представлены работы, опубликованные с 2021 по 2024 год, результаты которых обладают потенциалом усиления доказательности в вопросе раннего контроля ритма и позволяют расширить рекомендации по применению катетерной аблации, основанные на принципах доказательной медицины.
Об авторах
С. Г. Канорский
ФГБОУ ВО «Кубанский государственный медицинский университет» МЗ РФ
Россия
Россия
Канорский Сергей Григорьевич
Краснодар, ул. Митрофана Седина, д. 4
Л. В. Полищук
ФГБОУ ВО «Кубанский государственный медицинский университет» МЗ РФ
Россия
Россия
Краснодар, ул. Митрофана Седина, д. 4
Список литературы
1. Marcusohn E, Postnikov M, Kobo O, et al. Factors associated with left ventricular function recovery in patients with atrial fibrillation related cardiomyopathy. Isr Med As soc J. 2022;24(2): 101-106.
2. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circu lation. 2024;149(1): e1-e156. https://doi.org/10.1161/CIR.0000000000001193.
3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5): 373-498.https://doi.org/10.1093/eurheartj/ehaa612.
4. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021; 384:305-315. https://doi.org/10.1056/NEJMoa2029980.
5. Kim D, Yang PS, You SC, et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ. 2021;373: n991. https://doi.org/10.1136/bmj.n991.
6. Dickow J, Kirchhof P, Van Houten HK, et al. Generalizability of the EAST-AFNET 4 Trial: assessing outcomes of early rhythm-control therapy in patients with atrial fibrillation. J Am Heart Assoc. 2022;11: 1-11. https://doi.org/10.1161/JAHA.121.024214.
7. Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14): 1305-1316. https://doi.org/10.1056/NEJMoa2019422.
8. Rillig A, Magnussen C, Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation. 2021;144: 845-858. https://doi.org/10.1161/CIRCULATIONAHA.121.056323.
9. Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation. 2021;143: 1377-1390. https://doi.org/10.1161/CIRCULATIONAHA.120.050991.
10. Koldenhof T, Wijtvliet PEPJ, Pluymaekers NAHA, et al. Rate control drugs differ in the prevention of progression of atrial fibrillation. EP Europace. 2022;24(3): 384-389. https://doi.org/10.1093/europace/euab191.
11. Yang WY, Du X, Fawzy AM, et al. Associations of atrial fibrillation progression with clinical risk factors and clinical prognosis: a report from the Chinese Atrial Fibrillation Registry study. J Cardiovasc Electrophysiol. 2021;32: 333-341. https://doi.org/10.1111/jce.14826.
12. Sgreccia D, Manicardi M, Malavasi VL, et al. Comparing outcomes in asymptomatic and symptomatic atrial fibrillation: a systematic review and meta-analysis of 81,462 patients. J Clin Med. 2021;10: 3979. https://doi.org/10.3390/jcm10173979.
13. Willems S, Borof K, Brandes A, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2022;43: 1219-1230. https://doi.org/10.1093/eurheartj/ehab593.
14. Hermans ANL, Pluymaekers N, Lankveld TAR, et al. Clinical utility of rhythm control by electrical cardioversion to assess the association between selfreported symptoms and rhythm status in patients with persistent atrial fibrillation. Int J Cardiol Heart Vasc. 2021;36: 100870. https://doi.org/10.1016/j.ijcha.2021.100870.
15. Bodagh N, Yap R, Kotadia I, et al. Impact of catheter ablation versus medical therapy on cognitive function in atrial fibrillation: a systematic review. J Interv Card Elec trophysiol. 2022;65(1): 271-286. https://doi.org/10.1007/s10840-022-01196-y.
16. Kim D, Yang PS, You SC, et al. Association of rhythm control with incident dementia among patients with atrial fibrillation: a nationwide population-based cohort study. Age Ageing. 2022;51(1): afab248. https://doi.org/10.1093/ageing/afab248.
17. Abe Y, Takahashi Y, Shibata T. Looking into the mechanistic link between mitral regurgitation and atrial fibrillation. Cardiol Clin. 2021;39: 281-288. https://doi.org/10.1016/j.ccl.2021.01.010
18. Soulat-Dufour L, Lang S, Addetia K, et al. Restoring sinus rhythm reverses cardiac remodeling and reduces valvular regurgitation in patients with atrial fibrillation. J Am Coll Cardiol. 2022;79: 951-961. https://doi.org/10.1016/j.jacc.2021.12.029.
19. Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384(4): 316-324. https://doi.org/10.1056/NEJMoa2029554.
20. Andrade JG, Deyell MW, Macle L, et al. Progression of atrial fibrillation after cryoablation or drug therapy. N Engl J Med. 2023; 388(2):105-116. https://doi.org/10.1056/NEJMoa2212540.
21. Yalin K, Ikitimur B, Aksu T, et al. Catheter ablation for atrial fibrillation in patients ≤30 years of age. Am J Cardiol. 2022;166: 53-57. https://doi.org/10.1016/j.amjcard.2021.11.020.
22. El Assaad I, Hammond BH, Kost LD, et al. Management and outcomes of atrial fibrillation in 241 healthy children and young adults: revisiting “lone” atrial fibrillation-a multi-institutional PACES collaborative study. Heart Rhythm. 2021;18(11): 1815-1822. https://doi.org/10.1016/j.hrthm.2021.07.066.
23. Chew DS, Li Y, Cowper PA, et al. Cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation: the CABANA randomized clinical trial. Circulation. 2022;146(7):535-547. https://doi.org/10.1161/CIRCULATIONAHA.122.058575.
24. Тепцова ТС, Мусина НЗ, Омельяновский ВВ. Оценка референтного значения инкрементального показателя «затраты-эффективность» для российской системы здравоохранения. Фармакоэкономика. Современная Фармакоэкономика и Фармакоэпидемиология. 2020;13(4) :367-376. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.071.
25. Kuck K-H, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). Europace. 2021;23(3): 362-369. https://doi.org/10.1093/europace/euaa298.
26. Monahan KH, Bunch TJ, Mark DB, et al. Influence of atrial fibrillation type on outcomes of ablation vs. drug therapy: results from CABANA. Europace. 2022;24(9): 1430-1440. https://doi.org/10.1093/europace/euac055.
27. Friedman DJ, Field ME, Rahman M, et al. Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation. Heart Rhythm O2. 2021;2(1): 28-36. https://doi.org/10.1016/j.hroo.2020.12.017.
28. Bahnson TD, Giczewska A, Mark DB, et al. Association between age and outcomes of catheter ablation versus medical therapy for atrial fibrillation: results from the CABANA trial. Circulation. 2022;145(11): 796-804. https://doi.org/10.1161/CIRCULATIONAHA.121.055297.
29. Waranugraha Y, Rizal A, Rohman MS, et al. Prophylactic cavotricuspid isthmus ablation in atrial fibrillation without documented typical atrial flutter: a systematic review and meta-analysis. Arrhythm Electrophysiol Rev. 2022;11: e10. https://doi.org/10.15420/aer.2021.37.
30. Gupta D, Ding WY, Calvert P, et al. Cryoballoon pulmonary vein isolation as first-line treatment for typical atrial flutter. Heart. 2023;109(5): 364-371. https://doi.org/10.1136/heartjnl-2022-321729..
31. Kim JY, Park HS, Park HW, et al. Clinical outcomes of rhythm control strategies for asymptomatic atrial fibrillation according to the quality-of-life score: the CODEAF (Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation) registry. J Am Heart Assoc. 2022;11: e025956. https://doi.org/10.1161/JAHA.122.02595.
Рецензия
Для цитирования:
Канорский С.Г., Полищук Л.В. Стратегия контроля ритма при фибрилляции предсердий: современное состояние проблемы. Вестник аритмологии. 2024;31(2):e5-e14. https://doi.org/10.35336/VA-1335. EDN: BYUMYF
For citation:
Kanorskii S.G., Polischuk L.V. Rhythm control strategy in atrial fibrillation: state of the art. Journal of Arrhythmology. 2024;31(2):e5-e14. https://doi.org/10.35336/VA-1335. EDN: BYUMYF
Просмотров:
911
Послать статью по эл. почте 